Open Access Open Badges Research article

Rad9 modulates the P21WAF1 pathway by direct association with p53

Kazuhiro Ishikawa12, Hideshi Ishii2, Yoshiki Murakumo3, Koshi Mimori4, Masahiko Kobayashi5, Ken-ichi Yamamoto5, Masaki Mori4, Hiroshi Nishino1, Yusuke Furukawa2 and Keiichi Ichimura1*

Author Affiliations

1 Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University School of Medicine, Tochigi, Japan

2 Center for Molecular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan

3 Department of Pathology, Nagoya University Graduate School of Medicine, Aichi, Japan

4 Institute of Bioregulation, Kyushu University, Ohita, Japan

5 Kanazawa University Cancer Research Institute, Ishikawa, Japan

For all author emails, please log on.

BMC Molecular Biology 2007, 8:37  doi:10.1186/1471-2199-8-37

Published: 21 May 2007



Previous studies suggest that human RAD9 (hRad9), encoding a DNA damage checkpoint molecule, which is frequently amplified in epithelial tumor cells of breast, lung, head and neck cancer, participates in regulation of the tumor suppressor p53-dependent transactivation of pro-survival P21WAF1. This study examined the exact mechanism of the hRad9 function, especially through the phosphorylation of the C-terminus, in the transcription regulation of P21WAF1.


The transfection of phosphorylation-defective hRAD9 mutants of C-terminus resulted in reduction of the p53-dependent P21WAF1 transactivation; the knockdown of total hRad9 elicited an increased P21WAF1 mRNA expression. Immunoprecipitation and a ChIP assay showed that hRad9 and p53 formed a complex and both were associated with two p53-consensus DNA-binding sequences in the 5' region of P21WAF1 gene. The association was reduced in the experiment of phosphorylation-defective hRAD9 mutants.


The present study indicates the direct involvement of hRad9 in the p53-dependent P21WAF1 transcriptional mechanism, presumably via the phosphorylation sites, and alterations of the hRad9 pathway might therefore contribute to the perturbation of checkpoint activation in cancer cells.